# Enterasense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enterasense

- Industry: Medical Devices & Equipment
- Headquarters: Galway, Ireland
- Website: www.enterasense.com
- Total disclosed funding: $3.3M
- Latest round: Series A (Nov 3, 2021)
- Investors on record: 2

## About

Established in 2015 and based in Galway, Ireland, Enterasense Ltd. develops medical devices that detect and monitor the presence of bleeding in the gastrointestinal tract with its licensed technology agreement from Brigham and Women’s Hospital and Harvard Medical School. Subsequently, the firm successfully secured an initial seed funding of €1m from private investors in 2018, and an additional €2.5m from an EU Horizon in 2019.

The firm’s current CEO is Donal Devery, one of the co-founders, who has experience in founding and operating the biomedical company Vysera Biomedical Limited prior to the foundation of EnteraSense Limited. Daragh Sharkey is a current Chief Commercial Officer who is experienced in driving commercial growth and managing Distribution networks. Chiara DiCarlo is a Chief Technology Officer, who is an experienced Biomedical Engineer leading product development and technical activities of the firm.

As a MedTech company, its team of entrepreneurs, executives, engineers, and physicians developed an ingestible capsule device called PillSense and a reusable external receiver aiming for patient outcomes improvement, time efficiency, and healthcare cost reduction. PillSense is equipped with optical technology to detect and monitor Upper Gastrointestinal Bleeding (UGIB) and transmits data to an external receiver in real-time which enables an immediate diagnosis and intervention.

## Funding rounds

- Series A, Nov 3, 2021, $3.3M — University of Tokyo Edge Capital Partners, Enterprise Ireland

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Series A